Landscapes / Targets
APRIL
5 drugs act on APRIL, in 14 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs5
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Receptor molecules, native or modified |
Approved in China | Mar 2027Phase 3 trial completes | |||
| How it works | A decoy protein that soaks up a signal molecule before it can reach the body's cells | ||||
| Next date | Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Generalized Myasthenia Gravis, Primary Sjogren's Disease | ||||
| Open drug page | |||||
Receptor molecules, native or modified |
Approved | Nov 2027Phase 2 trial completes | |||
| How it works | A decoy protein that soaks up a signal molecule before it can reach the body's cells | ||||
| Next date | Nov 2027 · Phase 2 trial completes | ||||
| Also tested for | Berger Disease, IgA Nephropathy (IgAN) and 7 more | ||||
| Open drug page | |||||
BAFF/APRIL dual inhibitor (TACI-Fc fusion protein) |
Vertex Pharmaceuticals · Public VRTX |
Filed | 12 Dec 2027Phase 3 trial completes | ||
| Next date | 12 Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | Immunoglobulin A Nephropathy, Lupus Nephritis and 4 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Jun 2028Phase 1/2 trial completes | |||
| Next date | Jun 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Immunoglobulin A Nephropathy | ||||
| Open drug page | |||||
— |
Phase 1 | Apr 2027Phase 1 trial completes | |||
| Next date | Apr 2027 · Phase 1 trial completes | ||||
| Also tested for | RPS19 Deficient Diamond-Blackfan Anemia | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 5 of 5 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026